Discovery of TCRs targeting novel antigens using Deep Immunomics Invited by Dr Jérémie Poshmann

Dr Katja FINK, Senior Director Discovery, ImmunoScape
 

Dr. Katja Fink has more than 20 years of experience in basic and applied immunology research. She holds a Master in Biochemistry from the University of Zurich and a PhD in Immunology from the ETH in Zurich, Switzerland. After post-doctoral studies at Novartis, Dr. Fink became a Principal Investigator at A*STAR, Singapore, studying and developing therapies for dengue for ten years. She then led antibody discovery efforts at Humabs, Switzerland, a subsidiary of Vir Biotechnology, San Francisco, before joining ImmunoScape in Singapore. Her role at ImmunoScape is to guide the discovery of clinically relevant tumor-specific TCRs for the development of TCR-based immunotherapies.